{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:01:50Z","timestamp":1791478910622,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["16H06277"],"award-info":[{"award-number":["16H06277"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP17pc0101006"],"award-info":[{"award-number":["JP17pc0101006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01605-6","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:02:50Z","timestamp":1732147370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Can the clinical sign \u201chead-turning sign\u201d and simple questions in \u201cNeucop-Q\u201d predict amyloid \u03b2 pathology?"],"prefix":"10.1186","volume":"16","author":[{"given":"Yugaku","family":"Dat\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogyoku","family":"Bun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Momota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Shikimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Shimohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Oosumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Jinzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"1","key":"1605_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-016-0188-8","volume":"8","author":"M Prince","year":"2016","unstructured":"Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1605_CR2","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1017\/S1041610217001181","volume":"29","author":"P Soysal","year":"2017","unstructured":"Soysal P, Usarel C, Ispirli G, Isik AT. Attended with and head-turning sign can be clinical markers of cognitive impairment in older adults. Int Psychogeriatr. 2017;29(11):1763\u20139.","journal-title":"Int Psychogeriatr"},{"issue":"8","key":"1605_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/jnnp-2011-301804","volume":"83","author":"AJ Larner","year":"2012","unstructured":"Larner AJ. Head turning sign: pragmatic utility in clinical diagnosis of cognitive impairment. J Neurol Neurosurg Psychiatry. 2012;83(8):852\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1605_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/psyg.12289","volume":"18","author":"AT Isik","year":"2018","unstructured":"Isik AT, Soysal P, Kaya D, Usarel C. Triple test, a diagnostic observation, can detect cognitive impairment in older adults. Psychogeriatrics. 2018;18(2):98\u2013105.","journal-title":"Psychogeriatrics"},{"issue":"5","key":"1605_CR5","doi-asserted-by":"publisher","first-page":"e0233225","DOI":"10.1371\/journal.pone.0233225","volume":"15","author":"Y Date","year":"2020","unstructured":"Date Y, Sugiyama D, Tabuchi H, Saito N, Konishi M, Eguchi Y, et al. The utility of simple questions to evaluate cognitive impairment. PLoS ONE. 2020;15(5):e0233225.","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"1605_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000486531","volume":"46","author":"J Duraes","year":"2018","unstructured":"Duraes J, Tabuas-Pereira M, Araujo R, Duro D, Baldeiras I, Santiago B, et al. The Head turning sign in dementia and mild cognitive impairment: its relationship to Cognition, Behavior, and cerebrospinal fluid biomarkers. Dement Geriatr Cogn Disord. 2018;46(1\u20132):42\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"1605_CR7","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1212\/WNL.0000000000201389","volume":"100","author":"S Shimohama","year":"2023","unstructured":"Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M, et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology. 2023;100(3):e264\u201374.","journal-title":"Neurology"},{"issue":"5\u20136","key":"1605_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000464322","volume":"77","author":"K Mashima","year":"2017","unstructured":"Mashima K, Ito D, Kameyama M, Osada T, Tabuchi H, Nihei Y, et al. Extremely low prevalence of amyloid Positron Emission Tomography Positivity in Parkinson\u2019s Disease without Dementia. Eur Neurol. 2017;77(5\u20136):231\u20137.","journal-title":"Eur Neurol"},{"issue":"4","key":"1605_CR9","doi-asserted-by":"publisher","first-page":"fcab190","DOI":"10.1093\/braincomms\/fcab190","volume":"3","author":"T Tezuka","year":"2021","unstructured":"Tezuka T, Takahata K, Seki M, Tabuchi H, Momota Y, Shiraiwa M, et al. Evaluation of [(18)F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 2021;3(4):fcab190.","journal-title":"Brain Commun"},{"issue":"3","key":"1605_CR10","doi-asserted-by":"publisher","first-page":"e2499","DOI":"10.1002\/brb3.2499","volume":"12","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Yamao T. Software development for quantitative analysis of brain amyloid PET. Brain Behav. 2022;12(3):e2499.","journal-title":"Brain Behav"},{"issue":"1","key":"1605_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13195-023-01296-5","volume":"15","author":"S Bun","year":"2023","unstructured":"Bun S, Ito D, Tezuka T, Kubota M, Ueda R, Takahata K, et al. Performance of plasma Abeta42\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Alzheimers Res Ther. 2023;15(1):149.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1605_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and Non-alzheimer\u2019s Disease tauopathies. Neuron. 2021;109(1):42\u2013e588.","journal-title":"Neuron"},{"key":"1605_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2021.08.066","volume":"576","author":"K Yamashita","year":"2021","unstructured":"Yamashita K, Watanabe S, Ishiki K, Miura M, Irino Y, Kubo T, et al. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for beta-amyloid (1\u201340) and (1\u201342) in plasma samples. Biochem Biophys Res Commun. 2021;576:22\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1605_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-022-01029-0","volume":"14","author":"K Yamashita","year":"2022","unstructured":"Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, et al. Fully automated and highly specific plasma beta-amyloid immunoassays predict beta-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimers Res Ther. 2022;14(1):86.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1605_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77(11):1408\u201319.","journal-title":"JAMA Neurol"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"117440","DOI":"10.1016\/j.jns.2021.117440","volume":"425","author":"K Ishizuchi","year":"2021","unstructured":"Ishizuchi K, Takizawa T, Tezuka T, Takahata K, Seki M, Tabuchi H, et al. A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [(18)F]PM-PBB3 tau PET. J Neurol Sci. 2021;425:117440.","journal-title":"J Neurol Sci"},{"key":"1605_CR17","doi-asserted-by":"crossref","unstructured":"Mashima K, Konishi M, Tezuka T, Ito D, Mimura M. A case of tauopathy with auditory agnosia and dysprosody diagnosed by [(18)F]PM-PBB3 tau PET scan. Neurol Sci. 2021.","DOI":"10.1007\/s10072-021-05287-y"},{"issue":"6","key":"1605_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/mds.28983","volume":"37","author":"T Tezuka","year":"2022","unstructured":"Tezuka T, Takahata K, Tagai K, Ueda R, Ito D, Takeda H, et al. Progressive Ataxia and Palatal Tremor showing characteristic tau depositions in [(18) F]PM-PBB3 PET. Mov Disord. 2022;37(6):1317\u20139.","journal-title":"Mov Disord"},{"issue":"5","key":"1605_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/pcn.13526","volume":"77","author":"Y Momota","year":"2023","unstructured":"Momota Y, Liang KC, Horigome T, Kitazawa M, Eguchi Y, Takamiya A, et al. Language patterns in Japanese patients with Alzheimer disease: a machine learning approach. Psychiatry Clin Neurosci. 2023;77(5):273\u201381.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"7691","key":"1605_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"5","key":"1605_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma amyloid as Prescreener for the Earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358.","journal-title":"Ann Neurol"},{"issue":"5","key":"1605_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1605_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1605_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397.","journal-title":"Nat Med"},{"issue":"1","key":"1605_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1):68.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1605_CR26","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316.","journal-title":"Brain"},{"issue":"2","key":"1605_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med"},{"issue":"4","key":"1605_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Dore V, et al. Plasma Abeta42\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19(4):1117\u201334.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1605_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4997\/jrcpe.2019.416","volume":"49","author":"M Ghadiri-Sani","year":"2019","unstructured":"Ghadiri-Sani M, Larner AJ. Head turning sign. J R Coll Physicians Edinb. 2019;49(4):323\u20136.","journal-title":"J R Coll Physicians Edinb"},{"issue":"1","key":"1605_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000332605","volume":"1","author":"T Fukui","year":"2011","unstructured":"Fukui T, Yamazaki T, Kinno R. Can the \u2018head-turning sign\u2019 be a clinical marker of Alzheimer\u2019s disease? Dement Geriatr Cogn Dis Extra. 2011;1(1):310\u20137.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"5","key":"1605_CR31","doi-asserted-by":"publisher","first-page":"e0197468","DOI":"10.1371\/journal.pone.0197468","volume":"13","author":"M Matsushita","year":"2018","unstructured":"Matsushita M, Yatabe Y, Koyama A, Katsuya A, Ijichi D, Miyagawa Y, et al. Are saving appearance responses typical communication patterns in Alzheimer\u2019s disease? PLoS ONE. 2018;13(5):e0197468.","journal-title":"PLoS ONE"},{"issue":"Pt 9","key":"1605_CR32","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377.","journal-title":"Brain"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01605-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T01:03:21Z","timestamp":1732151001000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01605-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01605-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Certified Review Board of Keio University (#N20170237) approved the study design and protocol. The study was conducted in accordance with the Declaration of Helsinki. All participants (plus their proxies as needed) provided written informed consent for participation in the study. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; , ID# UMIN000032027) and Japan Registry of Clinical Trials (jRCT; , ID# jRCTs031180225).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daisuke Ito has received honorariums from Daiichi Sankyo, Nihon Medi-Physics, KOWA, and Eizai; there are no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}